Skip to content
10-K

Annual Report

ESTRELLA IMMUNOPHARMA, INC. ESLA ESLAW

0001213900-26-029357

← back to feed
Filed
Mar 18, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 36.82M sh
Shares Diluted FY 2025 · Dec 31, 2024 36.52M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$1.79M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$3.11M
Cash And Equivalents FY 2025 · Dec 31, 2025 $1.38M
Cash And Equivalents FY 2025 · Dec 31, 2024 $916.92K
Stockholders Equity FY 2025 · Dec 31, 2025 −$10.37M
Stockholders Equity FY 2025 · Dec 31, 2024 $143.73K
Stockholders Equity FY 2025 · Jun 30, 2024 $4.27M
Current Liabilities FY 2025 · Dec 31, 2025 $13.54M
Current Liabilities FY 2025 · Dec 31, 2024 $3M
Total Liabilities FY 2025 · Dec 31, 2025 $13.54M
Total Liabilities FY 2025 · Dec 31, 2024 $3M
Current Assets FY 2025 · Dec 31, 2025 $1.68M
Current Assets FY 2025 · Dec 31, 2024 $1.64M
Total Assets FY 2025 · Dec 31, 2025 $3.18M
Total Assets FY 2025 · Dec 31, 2024 $3.14M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.35
Eps Diluted FY 2025 · Dec 31, 2024 −$0.12
Eps Basic FY 2025 · Dec 31, 2025 −$0.35
Eps Basic FY 2025 · Dec 31, 2024 −$0.12
Sga Expense FY 2025 · Dec 31, 2025 $2.81M
Sga Expense FY 2025 · Dec 31, 2024 $1.57M
Rd Expense FY 2025 · Dec 31, 2025 $10.25M
Rd Expense FY 2025 · Dec 31, 2024 $2.86M
Net Income FY 2025 · Dec 31, 2025 −$13.06M
Net Income FY 2025 · Dec 31, 2024 −$4.43M
Operating Income FY 2025 · Dec 31, 2025 −$13.06M
Operating Income FY 2025 · Dec 31, 2024 −$4.43M
Stock Repurchased FY 2025 · Jan 30, 2024 $1M